skin cancer Archives -

Sanofi/Regeneron’s Libtayo set for new skin cancer use

Richard Staines basal cell carcinoma, cancer, Oncology, R&D, Regeneron, Sanofi, skin cancer 0 Comment

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings

Sanofi/Regeneron’s Libtayo set for new skin cancer use

https://pharmaphorum.com/news/sanofi-regenerons-libtayo-set-for-new-skin-cancer-use/

News/ News/ Oncology

Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1

Richard Staines Almirall, Bioniz, cancer, M&A, skin cancer 0 Comment

Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and

Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1

https://pharmaphorum.com/news/almirall-strikes-option-deal-to-buy-bioniz-and-dermatology-drug-bnz-1/

Digital/ News/ News/ News/ Oncology

Smartphone app provides skin cancer early warning service

Richard Staines digital health, LEO Pharma, skin cancer, SkinVision 0 Comment

The makers of a smartphone app are hoping that it could be used to play a crucial role

Smartphone app provides skin cancer early warning service

https://pharmaphorum.com/news/smartphone-app-provides-skin-cancer-early-warning-service/

Market Access/ News/ News/ News/ Oncology

Immediately after EU nod, England’s NHS funds Sanofi skin cancer drug

Richard Staines cancer, market access, Sanofi, skin cancer 0 Comment

Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer

Immediately after EU nod, England’s NHS funds Sanofi skin cancer drug

https://pharmaphorum.com/news/immediately-after-eu-nod-englands-nhs-funds-sanofi-skin-cancer-drug/

News

InflaRx flatlines after skin disease drug flops in midstage trial

Phil Taylor InflaRX, skin cancer 0 Comment

Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug

InflaRx flatlines after skin disease drug flops in midstage trial

https://pharmaphorum.com/news/inflarx-flatlines-skin-disease-drug-midstage-trial/

News/ News/ Oncology

NHS funds BMS’ Opdivo to prevent skin cancer returning

Richard Staines Bristol-Myers Squibb, cancer, Merck & Co, skin cancer 0 Comment

NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer

NHS funds BMS’ Opdivo to prevent skin cancer returning

https://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/

Oncology/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Quality of life increasingly important in skin cancer, say doctors at this year’s ESMO

Richard Staines ESMO 2018, quality of life, skin cancer 0 Comment

The factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved

Quality of life increasingly important in skin cancer, say doctors at this year’s ESMO

https://pharmaphorum.com/views-analysis-oncology/quality-of-life-increasingly-important-in-skin-cancer-esmo/

News/ News/ Oncology

EU regulators back BMS’ Opdivo in new skin cancer use

Richard Staines Bristol-Myers Squibb, cancer, Merck & Co, skin cancer 0 Comment

Bristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after

EU regulators back BMS’ Opdivo in new skin cancer use

https://pharmaphorum.com/news/eu-regulators-back-bms-opdivo-in-new-skin-cancer-use/

News/ News/ News/ Oncology/ R&D

Incyte shares down sharply after phase 3 skin cancer trial failure

Richard Staines cancer, Incyte, Merck & Co, skin cancer 0 Comment

Trial tested epacadostat pill in combination with Merck & Co’s Keytruda

Incyte shares down sharply after phase 3 skin cancer trial failure

https://pharmaphorum.com/news/incyte-shares-down-sharply-after-phase-3-skin-cancer-trial-failure/

Trending

skin cancer

Login